SiSaf exercises its option under licencing agreement on gene therapy for rare bone disease
SiSaf Ltd utilizes Intoolab’s Tzager AI Platform
SiSaf Ltd Announces US$13.2 Million Series B Financing
Non-invasive ocular siRNA delivery induces effective gene silencing in corneal epithelium
Next Page »
Find out more.
Okay, thank you